Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immatics appoints Rainer Kramer as CBO

This article was originally published in Scrip

Executive Summary

Immatics Biotechnologies, a biopharmaceutical firm that develops therapeutic cancer vaccines, has appointed Dr Rainer Kramer to the newly created role of chief business officer. The appointment is part of the firm's business strategy aimed at capitalising on its TUMAP-based cancer vaccine pipeline. The firm's lead products IMA901, for advanced renal cancer, and IMA910, for advanced colorectal cancer, have already yielded positive clinical results, says Immatics. Dr Kramer comes to the company from Signature Diagnostics, which specialises in oncology diagnostics, where he served as chief business officer. Before that he was vice-president of business development at Jerini.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016960

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel